The establishment of Pronexus Analytical AB in 2003 was preceded by a long-term scientific collaboration between the company founders, Professors Urban Ungerstedt, Kjell Fuxe, and Jan Kehr, affiliated at Department of Physiology and Pharmacology and Department of Neuroscience, Karolinska Institutet. Pronexus is a privately owned, fully proprietary and independent preclinical and analytical contract research organization.

Pronexus offers advanced services and collaborative projects in pharmacology, neurochemistry and tissue metabolism in experimental models of human diseases. The bioanalytical services include chromatographic and mass spectrometry techniques, as well as, immunoassays and enzymatic assays for quantification of neurotransmitters and other signaling molecules, metabolites, and drug levels in microdialysis samples, plasma, CSF, urine, culture media, cell lysates and tissue extracts.

Pronexus preclinical core expertise covers in vivo techniques for monitoring neurotransmitter release and metabolism, including microdialysis and biosensors, rodent models of CNS disorders, PK/PD studies and testing drug delivery systems. Pronexus bioanalytical laboratory and the animal research facility are GLP-compliant with full regulatory approvals.

Pronexus together with its strategic partners possess world leading expertise and know-how in screening and monitoring technologies from in vitro to in vivo models and translational studies up to microdosing and phase I trials.


The team of senior scientists (4 of them with PhD degree) with background from Karolinska Institutet, AstraZeneca comprise an internationally recognized group in the field of experimental neuropharmacology, chromatographic and mass spectrometric bioanalysis. Collectively we have more than 100 years of research experience both in academia and industry. We offer interactive communication with our clients, scientific input to study design and results discussion in relation to relevant literature data, flexibility in protocol design required particularly for exploratory, from pilot to full studies, method development and collaboration with academia.


QPS Neuro, Graz, Austria (

NeuroAssets, Switzerland (

Porsolt, France (

Preclinical Research Center, Lexington, KY, USA (

Clinical Trial Consultants, Sweden (

Offspring Biosciences, Sweden (

Quanteon, USA (

M Dialysis (

CMA Microdialysis (

Microbiotech/se (

U-FOLD - Forum for research on addiction to medical products and illegal drugs, Uppsala University, Sweden (

Karolinska Institutet Science Park, Sweden (

Tools of Science, Sweden (